BROMOCRIPTINE - A NOVEL APPROACH FOR MANAGEMENT OF TYPE 2 DIABETES MELLITUS

  • Anuj kumar pathak Rajendra Institute of Medical Sciences (RIMS) Ranchi ,Jharkhand
  • Praveen Kumar Sinha
  • Janardan Sharma
DOI https://doi.org/10.22270/jddt.v2i5.296

Abstract

Quick release formulation of  Bromocriptine mesylate is recently been approved by FDA (Food and Drug Administration) for the treatment of type 2 diabetes mellitus. Early morning dose of bromocriptine mesylate reduces the plasma prolactin level and increases the hypothalamic dopaminergic drive thereby reducing postprandial plasma glucose, triglyceride, and free fatty acid concentrations. Conventional preparation of bromocriptine are available in 2.5 mg or 5 mg tablets used for hyperprolactinemia and suppression of lactation. Studies have shown that quick release bromocriptine given in dose of 0.8-4.8 mg per day for a period of 6 month have successfully achieved target blood sugar. So the drug is well tolerated in antidiabetic dosage with mild side effects like nausea vomiting and fatigue. The central mechanism of action , good side effect profile and its effects to reduce adverse cardiovascular outcomes make it an attractive option for treatment of type 2 diabetes.

 

Key words : Bromociptine, diabetes, insulin resistance, quick release formulation, prolactin

Downloads

Download data is not yet available.

Author Biographies

Anuj kumar pathak, Rajendra Institute of Medical Sciences (RIMS) Ranchi ,Jharkhand

Junior Resident 3, Department of Pharmacology,

RIMS Ranchi

Praveen Kumar Sinha
Assistant Professor,Department of pharmacology,RIMS, Ranchi
Janardan Sharma
Professor and Head Department of pharmacology,RIMS, Ranchi
Crossmark
Statistics
293 Views | 289 Downloads
How to Cite
1.
pathak A, Sinha P, Sharma J. BROMOCRIPTINE - A NOVEL APPROACH FOR MANAGEMENT OF TYPE 2 DIABETES MELLITUS. JDDT [Internet]. 15Sep.2012 [cited 18Apr.2024];2(5). Available from: https://www.jddtonline.info/index.php/jddt/article/view/296
Issue
Vol 2 No 5 (2012): Volume 2, Issue 5, September-October 2012
Section
Review

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).